Kevin R. Sayer Sells 33,359 Shares of DexCom, Inc. (NASDAQ:DXCM) Stock

DexCom, Inc. (NASDAQ:DXCM) CEO Kevin R. Sayer sold 33,359 shares of the stock in a transaction dated Wednesday, January 29th. The shares were sold at an average price of $86.91, for a total value of $2,899,230.69. Following the completion of the sale, the chief executive officer now directly owns 319,037 shares in the company, valued at $27,727,505.67. This represents a 9.47 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website.

DexCom Stock Down 0.9 %

DexCom stock opened at $86.83 on Friday. The stock has a 50 day moving average of $80.77 and a two-hundred day moving average of $76.21. DexCom, Inc. has a twelve month low of $62.34 and a twelve month high of $142.00. The stock has a market capitalization of $33.92 billion, a price-to-earnings ratio of 51.99, a PEG ratio of 2.22 and a beta of 1.12. The company has a current ratio of 2.46, a quick ratio of 2.12 and a debt-to-equity ratio of 1.23.

Analyst Upgrades and Downgrades

A number of analysts have weighed in on DXCM shares. Wells Fargo & Company raised their price target on DexCom from $90.00 to $94.00 and gave the company an “overweight” rating in a research note on Wednesday, December 11th. Citigroup boosted their target price on DexCom from $85.00 to $91.00 and gave the stock a “buy” rating in a research note on Wednesday, December 11th. Robert W. Baird upgraded shares of DexCom from a “neutral” rating to an “outperform” rating and increased their price target for the company from $86.00 to $104.00 in a research note on Thursday, January 16th. StockNews.com downgraded shares of DexCom from a “buy” rating to a “hold” rating in a research report on Saturday, November 2nd. Finally, Oppenheimer dropped their target price on shares of DexCom from $115.00 to $105.00 and set an “outperform” rating on the stock in a research report on Friday, October 25th. Five equities research analysts have rated the stock with a hold rating, twelve have assigned a buy rating and two have issued a strong buy rating to the stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $99.29.

Institutional Investors Weigh In On DexCom

Hedge funds have recently modified their holdings of the stock. Versant Capital Management Inc purchased a new position in DexCom during the 4th quarter worth $25,000. Riverview Trust Co lifted its position in DexCom by 100.4% in the third quarter. Riverview Trust Co now owns 463 shares of the medical device company’s stock valued at $31,000 after purchasing an additional 232 shares during the period. Heck Capital Advisors LLC purchased a new stake in DexCom in the 4th quarter valued at approximately $38,000. RPg Family Wealth Advisory LLC acquired a new position in DexCom during the 3rd quarter worth approximately $57,000. Finally, Covestor Ltd raised its stake in shares of DexCom by 53.7% during the 3rd quarter. Covestor Ltd now owns 959 shares of the medical device company’s stock worth $64,000 after buying an additional 335 shares in the last quarter. 97.75% of the stock is owned by institutional investors and hedge funds.

DexCom Company Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.